A General Framework for Inhibitor Resistance in Protein Kinases

被引:51
作者
Balzano, Deborah [1 ]
Santaguida, Stefano [1 ]
Musacchio, Andrea [1 ,2 ]
Villa, Fabrizio [1 ]
机构
[1] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy
[2] Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany
来源
CHEMISTRY & BIOLOGY | 2011年 / 18卷 / 08期
关键词
LUNG-CANCER; ABL; IMATINIB; AURORA; PHOSPHORYLATION; MUTATIONS; MUTANTS; HASPIN; DOMAIN;
D O I
10.1016/j.chembiol.2011.04.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Protein kinases control virtually every aspect of normal and pathological cell physiology and are considered ideal targets for drug discovery. Most kinase inhibitors target the ATP binding site and interact with residue of a hinge loop connecting the small and large lobes of the kinase scaffold. Resistance to kinase inhibitors emerges during clinical treatment or as a result of in vitro selection approaches. Mutations conferring resistance to ATP site inhibitors often affect residues that line the ATP binding site and therefore contribute to selective inhibitor binding. Here, we show that mutations at two specific positions in the hinge loop, distinct from the previously characterized "gatekeeper," have general adverse effects on inhibitor sensitivity in six distantly related kinases, usually without consequences on kinase activity. Our results uncover a unifying mechanism of inhibitor resistance of protein kinases that might have widespread significance for drug target validation and clinical practice.
引用
收藏
页码:966 / 975
页数:10
相关论文
共 45 条
[1]
Aguilera Dolly G, 2009, Ther Clin Risk Manag, V5, P281
[2]
Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies [J].
Bikker, Jack A. ;
Brooijmans, Natasja ;
Wissner, Allan ;
Mansour, Tarek S. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (06) :1493-1509
[3]
Magic bullets for protein kinases [J].
Bishop, AC ;
Buzko, O ;
Shokat, KM .
TRENDS IN CELL BIOLOGY, 2001, 11 (04) :167-172
[4]
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors [J].
Blencke, S ;
Zech, B ;
Engkvist, O ;
Greff, Z ;
Örfi, L ;
Horváth, Z ;
Kéri, G ;
Ullrich, A ;
Daub, H .
CHEMISTRY & BIOLOGY, 2004, 11 (05) :691-701
[5]
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475
[6]
Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].
Capdeville, R ;
Buchdunger, E ;
Zimmermann, J ;
Matter, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502
[7]
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].
Carter, TA ;
Wodicka, LM ;
Shah, NP ;
Velasco, AM ;
Fabian, MA ;
Treiber, DK ;
Milanov, ZV ;
Atteridge, CE ;
Biggs, WH ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Mehta, SA ;
Patel, HK ;
Pao, W ;
Sawyers, CL ;
Varmus, H ;
Zarrinkar, PP ;
Lockhart, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016
[8]
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors [J].
Choi, Young Lim ;
Soda, Manabu ;
Yamashita, Yoshihiro ;
Ueno, Toshihide ;
Takashima, Junpei ;
Nakajima, Takahiro ;
Yatabe, Yasushi ;
Takeuchi, Kengo ;
Hamada, Toru ;
Haruta, Hidenori ;
Ishikawa, Yuichi ;
Kimura, Hideki ;
Mitsudomi, Tetsuya ;
Tanio, Yoshiro ;
Mano, Hiroyuki .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1734-1739
[10]
POTENTIAL POSITIVE AND NEGATIVE AUTO-REGULATION OF P60C-SRC BY INTERMOLECULAR AUTOPHOSPHORYLATION [J].
COOPER, JA ;
MACAULEY, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (12) :4232-4236